HC Wainwright & Co. Reiterates Buy on Immunocore Hldgs, Maintains $90 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Immunocore Hldgs (NASDAQ:IMCR) and maintained a $90 price target.
August 11, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immunocore Hldgs (NASDAQ:IMCR) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $90.
The reiteration of a 'Buy' rating and maintenance of a high price target by a reputable analyst firm like HC Wainwright & Co. is a positive signal for the stock. This could potentially lead to an increase in investor confidence and a short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100